-
Mashup Score: 0FDA Suggests Removing Oral Phenylephrine as OTC Monograph Nasal Decongestant Ingredient - 5 hour(s) ago
The announcement by the FDA resulted from an agency review of data on oral phenylephrine and a determination of its ineffectiveness as an active ingredient.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
In this geospatial analysis, findings indicate that geographic regions with more tanning bed facilities tend to report higher melanoma rates.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
Is tanning bed access linked to higher rates of #melanoma? New findings answer this question. While melanoma accounts for only around 1% of skin cancers within the US, it still results in the largest number of skin cancer deaths. View our summary here 👇 https://t.co/6R3A6mhE1x
-
-
Mashup Score: 0Roflumilast Reduces Disease Impact of Atopic Dermatitis - 9 hour(s) ago
New PRO data from the INTEGUMENT-1 and –2 studies were presented at the ACAAI 2024 Meeting.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
#Roflumilast cream significantly improved SCORAD, POEM, and DFI scores in #AtopicDermatitis patients compared to vehicle, indicating enhanced disease management and quality of life. Read more: https://t.co/2HP9LiO7bn
-
-
Mashup Score: 0Allergy Month in Review | October 2024 - 18 hour(s) ago
In this review of the month of October, some of the most notable advancements and news in the field of allergy were highlighted.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
This review of the HCPLive editorial team’s coverage of allergy news during October 2024 features a variety of noteworthy developments in the #allergy health space. Check out what you might have missed here 👇 https://t.co/LiiewQaK6p
-
-
Mashup Score: 0Filgotinib Continues to Show Efficacy for RA in LTE Studies - 20 hour(s) ago
Week 156 efficacy and safety data from the FINCH 4 study are consistent with that seen in FINCH 1, 2, and 3.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
Week 156 efficacy and safety data of filgotinib from the FINCH 4 study are consistent with that seen in FINCH 1, 2, and 3 in treating rheumatoid arthritis. #RheumTwitter https://t.co/y1XCKNS6Wp
-
-
Mashup Score: 0
Teva presents 2 findings at Psych Congress 2024: TEV’749’s effects on social function and quality of life in adults with schizophrenia and risperidone adherence patterns.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
Phase 3 trial shows TEV-‘749 injection improves social function & quality of life in adults with #schizophrenia, with safety similar to oral olanzapine. #PsychCongress2024 https://t.co/FLtvXHET2T
-
-
Mashup Score: 0FDA Accepts BLA for Denosumab Biosimilar - 1 day(s) ago
If approved, HLX14 would follow the first 2 denosumab biosimilar approvals in March 2024.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
If approved, HLX14 would follow the first 2 denosumab biosimilar approvals in March 2024. https://t.co/As1z3rxuyR
-
-
Mashup Score: 3
This interview with Kraft features a discussion regarding her team’s new data from the BATURA study on albuterol for patients’ asthma exacerbations.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
In a new interview with Monica Kraft, MD, of @DOMSinaiNYC, late-breaking data from the phase 3b BATURA study were discussed. Kraft highlighted that albuterol/budesonide (Airsupra) lowered the risk of severe #asthma exacerbations. See the interview 👇 https://t.co/Gs4rBCRtS8
-
-
Mashup Score: 0Hepatology Month in Review: October 2024 - 2 day(s) ago
This hepatology month in review spotlights hepatic pipeline news, research on treating and eliminating viral hepatitis, and HCPLive’s coverage of ACG 2024.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
Catch up on the latest news in #hepatology with our October 2024 month in review. Check it out here: https://t.co/Y9VleM84dK
-
-
Mashup Score: 0Study Highlights Limitations of Clinical Pathways for MASLD-Related Hepatocellular Carcinoma - 2 day(s) ago
Despite the number of individuals with MASLD-related HCC without cirrhosis who report a low FIB-4, current care pathways may not identify such patients for additional assessments.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
A new study showed that over 25% with #MASLD-related hepatocellular carcinoma (HCC) without cirrhosis had a low fibrosis-4 index (FIB-4), yet current clinical care pathways may not identify such patients for additional assessment. View more here 👇 https://t.co/KiC8BjMonE
-
🚨 The @US_FDA announced its recommendation that oral phenylephrine be removed as an active ingredient in over-the-counter monograph nasal decongenstants. Want to learn more about the decision? View our new summary here 👇 https://t.co/HfTJ45HKe9